Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes (original) (raw)

References

  1. Teramukai S, Okuda Y, Miyazaki S, Kawamori R, Shirayama M, Teramoto T . Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors. Hypertens Res 2016; 39: 113–118.
    Article CAS Google Scholar
  2. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–232.
    Article Google Scholar
  3. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J . Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813–1821.
    Article Google Scholar
  4. Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A . Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54: 32–43.
    Article CAS Google Scholar
  5. Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki S, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Toyama T, Hara A, Makino H . Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol 2014; 18: 613–620.
    Article CAS Google Scholar
  6. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ . Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493–1499.
    Article CAS Google Scholar
  7. Kimura K, Okada H, Tamura K, Nishi S, Wada T, Fukui T . Committee of Evidence-based Practice Guideline for the Treatment of CKD 2013. Evidence-based clinical practice guideline for CKD 2013. Clin Exp Nephrol 2014; 18: 339–423.
    Article Google Scholar
  8. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S . Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83: 517–523.
    Article CAS Google Scholar
  9. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C . Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
    Article Google Scholar
  10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
    Article CAS Google Scholar
  11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591.
    Article CAS Google Scholar
  12. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM . Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015; 314: 884–894.
    Article CAS Google Scholar
  13. Sato A . The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res 2015; 38: 367–374.
    Article CAS Google Scholar
  14. Nair S, Wilding JP . Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 34–42.
    Article CAS Google Scholar
  15. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ . Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420–428.
    Article CAS Google Scholar
  16. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253–387.
    Article Google Scholar
  17. Astrup AS, Nielsen FS, Rossing P, Ali S, Kastrup J, Smidt UM, Parving HH . Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens 2007; 25: 2479–2485.
    Article CAS Google Scholar
  18. Tamura K, Yamauchi J, Tsurumi-Ikeya Y, Sakai M, Ozawa M, Shigenaga A, Azuma K, Okano Y, Ishigami T, Toya Y, Yabana M, Tokita Y, Ohnishi T, Umemura S . Ambulatory blood pressure and heart rate in hypertensives with renal failure: comparison between diabetic nephropathy and non-diabetic glomerulopathy. Clin Exp Hypertens 2008; 30: 33–43.
    Article Google Scholar
  19. Eguchi K, Ishikawa J, Hoshide S, Pickering TG, Schwartz JE, Shimada K, Kario K . Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009; 22: 46–51.
    Article Google Scholar
  20. Ozawa M, Tamura K, Okano Y, Matsushita K, Yanagi M, Tsurumi-Ikeya Y, Oshikawa J, Hashimoto T, Masuda S, Wakui H, Shigenaga A, Azuma K, Ishigami T, Toya Y, Ishikawa T, Umemura S . Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives. Clin Exp Hypertens 2009; 31: 259–270.
    Article Google Scholar
  21. Oh SW, Han SY, Han KH, Cha RH, Kim S, Yoon SA, Rhu DR, Oh J, Lee EY, Kim DK, Kim YS . Morning hypertension and night non-dipping in patients with diabetes and chronic kidney disease. Hypertens Res 2015; 38: 889–894.
    Article CAS Google Scholar
  22. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE . Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128.
    Article CAS Google Scholar
  23. Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, Masaki T, Ohmori K, Kohno M, Ogata H, Nishiyama A . A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res 2016; 39: 415–422.
    Article CAS Google Scholar

Download references